Muscle strength is associated with fracture risk obtained by fracture risk assessment tool (FRAX) in women with breast cancer

Abstract

Background Women with breast cancer are at risk for the development of sarcopenia and occurrence of fractures. The initial and periodic screening of these conditions can prevent the risks of disability, poor quality of life, and death. The present study investigated the association between sarcopenia phenotypes and fracture risk, assessed by the Fracture Risk Assessment Tool (FRAX) in women with breast cancer. Methods Cross-sectional study. It included women aged between 40 and 80 years, diagnosed with Luminal subtype breast cancer, with time of diagnosis ≤ 12 months, who had not started endocrine therapy, did not have metastasis, had not been treated for another malignancy, and had no recurrences. Sociodemographic, habits and lifestyle, clinical, anthropometric, and body composition variables were considered. Muscle strength, skeletal muscle mass, and physical performance were investigated using handgrip strength (HGS), appendicular skeletal muscle mass index (ASMI), and Timed Up and Go test (TUGT), respectively. Fracture risk was assessed using FRAX. Multiple linear regression models were conducted to verify the association between exposure variables and sarcopenia phenotypes. A significance level of p < 0.05 was adopted for all tests using the SPPS 25.0 program. Results Sixty-two women with a mean age of 58.1 ± 10.4 years were evaluated. Of these, 66.1% self-declared to be non-white, 41.9% and 71.0% did not consume alcohol or smoke, respectively, and 61.3% were insufficiently active. A total of 45.2% had clinical stage II carcinoma and 65.5% had the invasive breast carcinoma histological subtype. There was a predominance of adequacy of HGS (88.7%), ASMI (94.5%), and TUGT (96.8%), as well as low risk of hip fractures (85.5%) and major fractures (82.3%). HGS remained associated with FRAX hip fractures (p = 0.007) and FRAX major fractures (p = 0.007) in the adjusted models, while ASMI was associated with body mass (p < 0.001). Conclusions Low muscle strength was the sarcopenia phenotype that remained associated with fracture risk in women with breast cancer, independently of sociodemographic factors, level of physical activity, and clinical factors. In addition to the assessment of probable sarcopenia, this measurement may point out the risk of fractures.

A precision‐based exercise program for patients with multiple myeloma

“…Alajlouni et al 45 demonstrated that measurement of muscle strength and physical performance further improves prediction of osteoporotic fracture risk compared with established scoring tools alone. Similar findings have been described for breast cancer patients 46 …”

“…Similar findings have been described for breast cancer patients. 46 We was continuously reported, but most patients were aware that they could positively influence these symptoms by performing PEP, which is essential for patients' self-efficacy and for reducing fear of pain/ injury due to movement. In line with this observation, patients performing PEP were also more likely to discontinue pain medication.…”

Subtrochanteric fracture of the femur following knee replacement surgery: A case series and review of the literature

“…In frail elderly patients, KA may protect against hip fracture by reducing the occurrence of falls. On the other hand, within the first month after KA, muscle strength is often decreased, which can elevate fracture risk [ 6 ].…”

PCDH7 as the key gene related to the co-occurrence of sarcopenia and osteoporosis

“…Sarcopenia may lack specific clinical features; patients with it may present with weakness, difficulty walking, slow gait, and thin and weak limbs ( Aoki et al, 2022 ). Sarcopenia may increase the risk of falls and fractures ( de Almeida Marques Bernabe et al, 2022 ), decrease the quality of daily living activities, and relate to many comorbidities such as cardiac disease ( Loh et al, 2022 ), diabetes ( Jun et al, 2022 ), and cognitive impairment ( Noda et al, 2022 )—although these symptoms can be easy to ignore ( Malmstrom et al, 2016 ; Mijnarends et al, 2018 ).…”